DRUGS MADE IN AMERICA ACQUISITION II CORP.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Apr 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $112.2K | — | — | $132.0K | — | — | $155.5K |
| Operating Income | — | $-112.2K | — | — | $-132.0K | — | — | $-155.5K |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $4.4M | — | — | $4.3M | — | — | $-46.2K |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | — | — | — | — | — | — | — |
| EPS (Diluted) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Basic) | 63.7M | 13.7M | 63.7M | 63.7M | 13.7M | 13.7M | 65.6M | 15.6M |
| Shares Outstanding (Diluted) | 63.7M | 13.7M | 63.7M | 63.7M | 13.7M | 13.7M | 65.6M | 15.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |